1657 related articles for article (PubMed ID: 26281148)
41. Hepatocyte growth factor and antibodies to HLA and MICA antigens in heart transplant recipients.
Pavlova YA; Malek I; Honsova E; Netuka I; Sochman J; Lodererova A; Kolesar L; Striz I; Skibova J; Slavcev A
Tissue Antigens; 2010 Nov; 76(5):380-6. PubMed ID: 20604893
[TBL] [Abstract][Full Text] [Related]
42. De novo donor specific antibodies and patient outcomes in renal transplantation.
DeVos JM; Patel SJ; Burns KM; Dilioglou S; Gaber LW; Knight RJ; Gaber AO; Land GA
Clin Transpl; 2011; ():351-8. PubMed ID: 22755430
[TBL] [Abstract][Full Text] [Related]
43. Benefits of rituximab combined with intravenous immunoglobulin for desensitization in kidney transplant recipients.
Vo AA; Choi J; Cisneros K; Reinsmoen N; Haas M; Ge S; Toyoda M; Kahwaji J; Peng A; Villicana R; Jordan SC
Transplantation; 2014 Aug; 98(3):312-9. PubMed ID: 24770617
[TBL] [Abstract][Full Text] [Related]
44. Clinical Relevance of Posttransplant DSAs in Patients Receiving Desensitization for HLA-incompatible Kidney Transplantation.
Vo AA; Aubert O; Haas M; Huang E; Zhang X; Choi J; Peng A; Najjar R; Sethi S; Ammerman N; Lim K; Jordan SC
Transplantation; 2019 Dec; 103(12):2666-2674. PubMed ID: 30883456
[TBL] [Abstract][Full Text] [Related]
45. Repeated cycles of high-dose intravenous immunoglobulin and plasmapheresis for treatment of late antibody-mediated rejection of renal transplants.
Lee CY; Lin WC; Wu MS; Yang CY; Yeh CC; Tsai MK
J Formos Med Assoc; 2016 Oct; 115(10):845-852. PubMed ID: 27542515
[TBL] [Abstract][Full Text] [Related]
46. Intensive plasmapheresis and intravenous immunoglobulin for treatment of antibody-mediated rejection after kidney transplant.
Ruangkanchanasetr P; Satirapoj B; Termmathurapoj S; Namkhanisorn K; Suaywan K; Nimkietkajorn V; Luesutthiviboon L
Exp Clin Transplant; 2014 Aug; 12(4):328-33. PubMed ID: 25095710
[TBL] [Abstract][Full Text] [Related]
47. Prevention and treatment of alloantibody-mediated kidney transplant rejection.
Bartel G; Schwaiger E; Böhmig GA
Transpl Int; 2011 Dec; 24(12):1142-55. PubMed ID: 21831227
[TBL] [Abstract][Full Text] [Related]
48. Impact of Tocilizumab (Anti-IL-6R) Treatment on Immunoglobulins and Anti-HLA Antibodies in Kidney Transplant Patients With Chronic Antibody-mediated Rejection.
Shin BH; Everly MJ; Zhang H; Choi J; Vo A; Zhang X; Huang E; Jordan SC; Toyoda M
Transplantation; 2020 Apr; 104(4):856-863. PubMed ID: 31385933
[TBL] [Abstract][Full Text] [Related]
49. Long-term experience of plasmapheresis in antibody-mediated rejection in renal transplantation.
Brown CM; Abraham KA; O'Kelly P; Conlon PJ; Walshe JJ
Transplant Proc; 2009 Nov; 41(9):3690-2. PubMed ID: 19917368
[TBL] [Abstract][Full Text] [Related]
50. Differential modulation of donor-specific antibodies after B-cell depleting therapies to cure chronic antibody mediated rejection.
Touzot M; Couvrat-Desvergnes G; Castagnet S; Cesbron A; Renaudin K; Cantarovich D; Giral M
Transplantation; 2015 Jan; 99(1):63-8. PubMed ID: 25029384
[TBL] [Abstract][Full Text] [Related]
51. Alemtuzumab induction therapy in highly sensitized kidney transplant recipients.
Lü TM; Yang SL; Wu WZ; Tan JM
Chin Med J (Engl); 2011 Mar; 124(5):664-8. PubMed ID: 21518554
[TBL] [Abstract][Full Text] [Related]
52. Impact of HLA antibodies on graft survival in long-term renal recipients with functional grafts.
Zeng Y; Liu Z; Liu Y; Fan Y; Guo Y; Qiu J
Urol Int; 2014; 92(3):328-33. PubMed ID: 24480999
[TBL] [Abstract][Full Text] [Related]
53. Analysis of anti-HLA antibodies in sensitized kidney transplant candidates subjected to desensitization with intravenous immunoglobulin and rituximab.
Lobashevsky AL; Higgins NG; Rosner KM; Mujtaba MA; Goggins WC; Taber TE
Transplantation; 2013 Jul; 96(2):182-90. PubMed ID: 23778648
[TBL] [Abstract][Full Text] [Related]
54. Beyond histology: lowering human leukocyte antigen antibody to improve renal allograft survival in acute rejection.
Everly MJ; Rebellato LM; Ozawa M; Briley KP; Catrou PG; Haisch CE; Terasaki PI
Transplantation; 2010 Apr; 89(8):962-7. PubMed ID: 20075791
[TBL] [Abstract][Full Text] [Related]
55. Living donor kidney transplantation in patients with donor-specific HLA antibodies enabled by anti-CD20 therapy and peritransplant apheresis.
Klein K; Süsal C; Schäfer SM; Becker LE; Beimler J; Schwenger V; Zeier M; Schemmer P; Macher-Goeppinger S; Scherer S; Opelz G; Morath C
Atheroscler Suppl; 2013 Jan; 14(1):199-202. PubMed ID: 23357165
[TBL] [Abstract][Full Text] [Related]
56. A report of the epidemiology of de novo donor-specific anti-HLA antibodies (DSA) in "low-risk" renal transplant recipients.
Rebellato LM; Everly MJ; Haisch CE; Ozawa M; Briley KP; Parker K; Catrou PG; Bolin P; Kendrick WT; Kendrick SA; Harland RC
Clin Transpl; 2011; ():337-40. PubMed ID: 22755428
[TBL] [Abstract][Full Text] [Related]
57. Antithymocyte globulin induction therapy adjusted for immunologic risk after heart transplantation.
Czer LS; Phan A; Ruzza A; Rafiei M; Setareh-Shenas S; Caceres M; Awad M; Soliman C; Mirocha J; De Robertis M; Kass RM; Trento A
Transplant Proc; 2013; 45(6):2393-8. PubMed ID: 23953554
[TBL] [Abstract][Full Text] [Related]
58. Utility of peritransplant and rescue intravenous immunoglobulin and extracorporeal immunoadsorption in lung transplant recipients sensitized to HLA antigens.
Appel JZ; Hartwig MG; Davis RD; Reinsmoen NL
Hum Immunol; 2005 Apr; 66(4):378-86. PubMed ID: 15866701
[TBL] [Abstract][Full Text] [Related]
59. Efficacy of immunoadsorption to reduce donor-specific alloantibodies in kidney-transplant candidates.
Rostaing L; Congy N; Aarnink A; Maggioni S; Allal A; Sallusto F; Game X; Kamar N
Exp Clin Transplant; 2015 Apr; 13 Suppl 1():201-6. PubMed ID: 25894155
[TBL] [Abstract][Full Text] [Related]
60. Bortezomib in ABO-incompatible kidney transplant desensitization: a case report.
Wong NL; O'Connell P; Chapman JR; Nankivell B; Kable K; Webster AC; Wong G
Nephrology (Carlton); 2015 Mar; 20 Suppl 1():22-4. PubMed ID: 25807854
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
